Tariq Musa, a director at Guardant Health , Inc. (NASDAQ:GH), recently reported the sale of 116 shares of the company’s common stock. The transaction, which took place on January 17, 2025, was executed at a price of $37.58 per share, totaling approximately $4,359. The stock has shown remarkable strength, delivering a 58% return over the past year, and currently trades near its 52-week high at $45.13. According to InvestingPro analysis, the company’s current market capitalization stands at $5.56 billion. Following this sale, Musa holds 2,944 shares in the company. The filing was submitted to the SEC on January 21, 2025. Wall Street analysts maintain a bullish outlook on the stock, with price targets ranging from $34 to $60. For deeper insights into insider trading patterns and comprehensive analysis, InvestingPro subscribers can access detailed research reports covering 1,400+ US stocks, including Guardant Health.
In other recent news, Guardant Health has been the focus of numerous analyst ratings. Raymond (NSE:RYMD) James reaffirmed its Outperform rating with a price target of $39, while TD Cowen maintained a Buy rating with a target of $42. BTIG raised its price target to $55, and Canaccord Genuity held firm with a $42 target. These ratings reflect a positive outlook for Guardant Health, particularly with recent developments in Medicare coverage for its Reveal test, designed to detect colon cancer recurrence.
The company’s strong revenue growth of 29.2% over the last year was highlighted by analysts. They anticipate that the expanded Medicare coverage and improvements in pricing could lead to a surge in clinical volumes, exceeding 20%. However, the company is not expected to achieve profitability this year.
Analysts also noted Guardant Health’s partnership with Boehringer Ingelheim to seek regulatory approval for Guardant360® CDx, a liquid biopsy test. This is considered a key development for the company. Investors are awaiting Guardant Health’s fourth-quarter results for further insights into its financial health and operational progress.
These recent developments underscore Guardant Health’s significant strides in the healthcare sector, with a particular focus on advanced diagnostics technologies. The company maintains a healthy financial position with a current ratio of 6.22, indicating strong liquidity to support its growth initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.